GSK gains FDA Orphan Drug Designation for risvutatug rezetecan, adding momentum to its fast-advancing solid-tumor pipeline.
Expansion plan includes doubling the number of sales reps, a new GoodRx partnership, and enhanced digital marketing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback